MiNK Therapeutics Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

Rhea-AI Summary

MiNK Therapeutics has submitted a draft registration statement on Form S-1 to the SEC for a proposed initial public offering (IPO) of its common stock. The share count and pricing details will be determined later, with the IPO expected to occur post-SEC review and contingent on market conditions. MiNK operates as a subsidiary of Agenus (NASDAQ: AGEN). This announcement follows compliance with Rule 135 under the Securities Act of 1933, clarifying that it does not represent an offer to sell or buy securities.

Positive

• Proposed IPO may enhance MiNK's capital for growth and development.
• Confidential filing indicates preparation for potential market entry.

Negative

• Details such as share count and price range remain undetermined, leading to uncertainty.
• Market conditions could affect the timing and success of the IPO.

NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics today announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC") relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The initial public offering is expected to take place after the SEC completes its review process, subject to market and other conditions. MiNK is a subsidiary of Agenus Inc. (NASDAQ: AGEN).

This press release is being made pursuant to, and in accordance with, Rule 135 under the Securities Act of 1933, as amended (the "Securities Act"), and shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act.

Contact
Agenus Investor Relations
Jan Medina, CFA
Agenus
781-674-4490
Jan.Medina@agenusbio.com

Agenus Media Relations
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com

FAQ

What is MiNK Therapeutics planning regarding its IPO?

MiNK Therapeutics has filed a draft registration statement on Form S-1 with the SEC for a proposed IPO.

When is MiNK's initial public offering expected to take place?

The IPO is anticipated after the SEC's review, subject to market conditions.

What stock symbol is related to MiNK Therapeutics?

MiNK operates as a subsidiary of Agenus, which trades under the stock symbol AGEN.

Are the details of the MiNK IPO already determined?

No, the number of shares and price range for the offering have yet to be determined.